Synapsoft logo
AI Insights from Disclosures
Searching...
HK inno.N Corporation 195940
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
HK inno.N Corporation engages in the prescription drug business and the H&B business. The prescription drug segment is led by K-CAP, Korea's 30th new drug, along with Lobazet and Akinzio, and the H&B segment recorded first-half 2024 revenue of KRW 431.9 billion and operating profit of KRW 41.6 billion, driven by the growth of key products such as Condition, Hutgaesu, and Biwoncheu.
Representative Director Gwak Dalwon
Founded April 1, 2014
Corporation Type KOSDAQ
Industry Classification Manufacture of medicaments
Corporate number 11011-5379692
Business number 201-86-38914
Phone Number 02-6477-0000
Fax Number 02-6477-0699
Website www.inno-n.com
Company Address 239 Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant